Navigation Links
Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
Date:5/8/2012

PHILADELPHIA, May 8, 2012 /PRNewswire/ -- The new prescription sleep aid Intermezzo (zolpidem tartrate) sublingual tablet CIV is the first and only prescription sleep aid approved by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep, and the patient has at least four hours of bedtime remaining before the planned time of waking. Intermezzo has gender-specific dosing (1.75 mg for adult women and 3.5 mg for adult men) taken only once per night as needed if a middle-of-the-night awakening is followed by difficulty returning to sleep. Intermezzo 1.75 mg is also the recommended dose for men and women over 65 years of age, patients with hepatic impairment, or patients taking concomitant CNS depressants.

In the double-blind, placebo-controlled, cross-over pharmacokinetic study in healthy volunteers, Intermezzo doses of 1.0 mg, 1.75 mg, and 3.5 mg were administered on two consecutive days to 11 women and 13 men. At the same dose, the plasma levels of zolpidem tartrate in women were approximately 45 percent higher than in men. The study found that women taking a 3.5 mg dose cleared the drug at a slower rate than men taking 3.5 mg (2.7 ml/min/kg vs. 4.00 ml/min/kg, respectively).

"Given that women clear the active ingredient in Intermezzo at a lower rate than men, the results of the study support a recommended lower dosage of Intermezzo for women and a higher dosage for men," said study co-author Thomas Roth, Ph.D., Director of Sleep Medicine at Henry Ford Hospital in Detroit.

Intermezzo was approved by the FDA in November 2011 and is available nationwide in spearmint-flavored sublingual tablets that are placed under the tongue and allowed to disintegrate completely before swallowing. Intermezzo contains a bicarbonate-carbonate buffer. On average, Intermezzo is rapidly absorbed in both genders, achieving peak mean plasma levels of zolpidem in
'/>"/>

SOURCE Purdue Pharma L.P.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012
2. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
3. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
4. Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
5. 12 Month TRAM Data Collated Using TIGR® Matrix Surgical Mesh in a Randomized Controlled Study Presented at MAPACS 2012
6. Johnson & Johnson to Provide Webcast Presentation of XARELTO® (rivaroxaban) Phase 3 Clinical Data Presented at the American College of Cardiologys Annual Scientific Sessions
7. Frost & Sullivan New Product Innovation Award Presented to Brainsway for Its Deep Transcranial Magnetic Stimulation (dTMS) Device
8. Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology
9. Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI): Phase III Data on Bayers Investigational Compound Regorafenib (BAY 73-4506) in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Or
10. nContacts Cardiac Ablation Technology to be Presented in Two Noteworthy Posters at Boston Atrial Fibrillation Symposium 2012
11. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML Presented at the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 The Parenteral Drug Association (PDA) ... post-approval changes protocols. The new initiative ... expressed by industry participants and regulatory authority representatives at ... in Washington, DC . Representatives of ... for the workshop. Attendees indicated openness to engaging regulators ...
(Date:9/19/2014)... DALLAS , Sept. 19, 2014 ... Market Outlook to 2020″, provides key ... General Surgery devices market. The report ... dollars, and volume (in units) within ... Cystoscopes, Colonoscopes, Sigmoidoscopes, Esophagoscopes & Gastroscopes, ...
(Date:9/19/2014)...  The board of directors of AbbVie Inc. (NYSE: ... of $0.42 per share.  The cash ... record at the close of business on Oct. 15, ... research-based biopharmaceutical company formed in 2013 following separation from ... dedicated people and unique approach to innovation to develop ...
Breaking Medicine Technology:PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5
... BRUNSWICK, N.J., Dec. 15, 2010 Johnson & Johnson ... Gorsky, currently Worldwide Chairman, Medical Devices & Diagnostics (MD&D) ... appointed Vice Chairmen of the Executive Committee and join ... Executive Officer, in an expanded Office of the Chairman. ...
... Control Risks , one of the world,s leading ... its annual review and forecast of business risk for the ... and security risk in 173 countries. 2011 will ... both politically and economically, as the world,s emerging economies use ...
Cached Medicine Technology:Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 2Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 3Control Risks Forecasts New Reality for Business in 2011 Brought by Emerging Markets, Legislation 2
(Date:9/20/2014)... -- As flu season approaches, the best way to ... flu shot and a checkup, according to an infectious ... vaccinate people against the flu, and also address other ... may provide flu shots for their customers, but they ... medical director of infection prevention and control for the ...
(Date:9/20/2014)... 2014 As concerns surrounding the ... in gynecological surgeries continue to grow, Bernstein Liebhard ... plans to end coverage for uterine morcellation. According ... month, Harrisburg, Pennsylvania-based Capital BlueCross will end coverage ... insurer said its decision was prompted by concerns ...
(Date:9/20/2014)... Traditionally dentists have advised their patients against drinking ... is re-visiting that advice and changing his stance after ... wine have on oral health. “There’s good news and great ... be beneficial in protecting against gum disease, and red wine ... coffee was from the September 2014 issue of Boston ...
(Date:9/20/2014)... 20, 2014 Earlier this week, Home Depot ... have had their credit card information pilfered by hackers, surpassing ... slew of headline articles like this one published ... eye opening numbers. , “Most people tend to focus ... it’s a way to score a game,” says Joe Caruso, ...
(Date:9/20/2014)... 2014 The Arizona Advanced Manufacturing ... celebrating National Manufacturing Day by opening its doors to ... and additive manufacturing labs will be offered between 10 ... MCC’s Southern and Dobson campus (1833 W. Southern Ave, ... D. , The AzAMI at MCC was established in ...
Breaking Medicine News(10 mins):Health News:Get a Flu Shot During Checkup, Doctor Says 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2
... 23 WebMD Health Corp. (Nasdaq: WBMD ) ... that executives of WebMD are scheduled to participate at the ... 25, 2009 at 12:40 p.m. ET. Investors, analysts and ... audio broadcast of the presentation over the Internet. The ...
... On Wednesday, February 25, 2009, the Institute for ... roundtable discussion bringing leading scientists in the field of ... significance (MGUS). The event is being cochaired by James ... at the IMBCR and Robert A. Kyle, MD, who ...
... with Crain,s Cleveland Business, today presented a 2009 NorTech ... development of a Biotech Platform to Detect, Monitor, and ... developed a set of diagnostic tests used by physicians ... by determining drug resistance and disease "strength" of the ...
... #1 FOR IMMEDIATE RELEASE , Egg-irony: High cholesterol food ... Chemistry , Researchers in Canada are reporting evidence that ... may reduce another heart disease risk factor high ... that act like a popular group of prescription medications in ...
... TAMPA, Fla., Feb. 23 /PRNewswire/ -- ... data management solutions company, today announced the release ... cleanses, standardizes and integrates data from multiple platforms. ... businesses encompassing small, mid-size and "Fortune 500" companies, ...
... Sunrise Senior Living, Inc. (NYSE: SRZ ) today ... on Monday, March 2, 2009, at 9 a.m. ET to ... Mark Ordan, chief executive officer, and Richard Nadeau, chief financial ... conference call is 877-795-3638 or 719-325-4841 (from outside the U.S.). ...
Cached Medicine News:Health News:International Panel of Experts Gather for Roundtable Consensus Regarding Multiple Myeloma Related Disease 2Health News:Case Western Reserve University faculty named 2009 NorTech Innovation Award winner 2Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 2Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 3Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 4Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 5Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 6Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 7Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 8Health News:Industry Leading Data Quality and Householding Software Receives New Functionality for Enhanced Performance and Speed 2Health News:Sunrise to Host Conference Call and Webcast to Discuss Fourth-Quarter and Full-Year 2008 Financial Results 2
The DSL-05-10-VZM Varicella Zoster IgM Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgM-class antibodies to Varicella Zoster Virus in human serum. This as...
Inquire...
The CALBIOTECH, INC. (CBI), Mumps IgM ELISA tests system is an enzyme linked immunosorbent assay (ELISA) for the detection of IgM class antibodies to Mumps in human serum or plasma....
... is comprised of the TEG analyzer and the ... picture of the formation and dissolution of the ... two systems. ,Haemoscope's TEG analyzer is the only ... the reliable and proven model developed by Prof. ...
Medicine Products: